Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mersana Teams With Teva To Develop Polymer Conjugate Cancer Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Linking fumagillin analogue with polymer should prevent CNS toxicities seen with previous fumagillin candidates.

You may also be interested in...

Mersana To Focus Fully On Anti-Cancer ADCs With $27M Recapitalization

Nearly ready to out-license its remaining small molecule drug conjugate candidate, Mersana will focus exclusively on developing Fleximer-based antibody-drug conjugates through collaborations with Endo and future partners.

Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration

Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.

Mersana Therapeutics Inc.

By linking drugs to a proprietary nanometer-scale polymer, Mersana Therapeutics can favorably affect properties of chemotherapeutic agents such as solubility, half-life, and accumulation in tumor tissue, thereby widening their therapeutic window.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts